New combo therapy aims to boost pancreatic cancer survival
NCT ID NCT06141031
First seen Mar 30, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This early-phase trial tests a new drug (TTI-101) combined with targeted radiation for people with pancreatic cancer that cannot be removed by surgery right away. The goal is to see if the combination is safe and can help keep the cancer from growing for longer. About 5 participants will take part in this study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Colorado
Aurora, Colorado, 80045, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.